This is a summary of the European public assessment report (EPAR) for Cometriq. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cometriq. For practical information about using Cometriq, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
Therapeutic Area (MeSH)
ATC Code
L01XE
ATC Item
蛋白激酶抑制剂
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| cabozantinib | N/A | 卡波替尼 |
EMA Name
Cometriq
Medicine Name
Cometriq
Aliases
N/A
